- Home
- NR vs CVAC Comparison
NR vs CVAC Comparison
Compare NR & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NR
- CVAC
- Stock Information
- Founded
- NR 1932
- CVAC 2000
- Country
- NR United States
- CVAC Germany
- Employees
- NR N/A
- CVAC N/A
- Industry
- NR Metal Fabrications
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- NR Industrials
- CVAC Health Care
- Exchange
- NR Nasdaq
- CVAC Nasdaq
- Market Cap
- NR 629.7M
- CVAC 637.1M
- IPO Year
- NR N/A
- CVAC 2020
- Fundamental
- Price
- NR $7.78
- CVAC $2.56
- Analyst Decision
- NR Strong Buy
- CVAC Hold
- Analyst Count
- NR 3
- CVAC 3
- Target Price
- NR $11.00
- CVAC $10.00
- AVG Volume (30 Days)
- NR 590.8K
- CVAC 556.8K
- Earning Date
- NR 11-07-2024
- CVAC 11-12-2024
- Dividend Yield
- NR N/A
- CVAC N/A
- EPS Growth
- NR N/A
- CVAC N/A
- EPS
- NR N/A
- CVAC N/A
- Revenue
- NR $748,372,000.00
- CVAC $70,565,734.00
- Revenue This Year
- NR N/A
- CVAC $123.97
- Revenue Next Year
- NR N/A
- CVAC N/A
- P/E Ratio
- NR N/A
- CVAC N/A
- Revenue Growth
- NR 93.70
- CVAC 75.11
- 52 Week Low
- NR $5.61
- CVAC $2.22
- 52 Week High
- NR $8.65
- CVAC $6.30
- Technical
- Relative Strength Index (RSI)
- NR 64.61
- CVAC 39.24
- Support Level
- NR $6.98
- CVAC $2.37
- Resistance Level
- NR $7.27
- CVAC $2.65
- Average True Range (ATR)
- NR 0.32
- CVAC 0.18
- MACD
- NR 0.06
- CVAC -0.02
- Stochastic Oscillator
- NR 87.71
- CVAC 31.67
About NR Newpark Resources Inc.
Newpark Resources Inc is a diversified supplier providing environmentally-sensitive products, as well as rentals and services to customers across multiple industries. The company has two operating segments: Industrial Solutions and Fluids Systems. Fluids Systems segment which generates the majority of the revenue, provides drilling, completion, and stimulation fluids products and related technical services to customers for oil, natural gas, and geothermal projects. Geographically, the company derives majority of its revenue from the United States and also has its presence in Canada, EMEA, Latin America, and Asia Pacific regions.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.